Drug Price Regulator Issues Notices To Lupin, Wockhardt, Others For Violating Price Control Norm - (Yahoo!India via NewsPoints Desk)

  • India's National Pharmaceutical Pricing Authority (NPPA) has issued notices to companies including Abbott, Cadila Healthcare and Dr. Reddy's Laboratories regarding non-compliance with price controls, as reported Yahoo!Finance Wednesday.

  • In the notification, the NPPA claims the drugmakers have launched formulations by altering scheduled formulations with dosages differing from those specified in the Drugs Price Control Order (DPCO) 2013.

  • Other drugmakers targeted by the notification include Alkem Laboratories, GlaxoSmithKline, Glenmark Pharmaceuticals, Lupin, Novartis India, Sanofi India, Unichem Laboratories and Wockhardt.

  • The NPPA has called on the companies to provide batch-wise production and sales details together with the corresponding maximum retail price information along with reasons for non-compliance with the provisions by June 15.

  • "If the replies are not received by the stipulated time, NPPA will proceed for taking further action in the matter as per DPCO 2013 and Essential Commodities Act, 1955," the regulator stated.

  • FirstWord Reports: Providing insight, analysis and expert opinion on important Pharma trends and challenging issues <Click here>

To read more NewsPoints articles, click here.